ASH Annual Meeting and Exposition | Conference

Ibrutinib Established as Standard for Older CLL Patients

December 2nd 2018

Ibrutinib as monotherapy and combined with rituximab significantly improved progression-free survival compared with bendamustine plus rituximab as frontline therapy for older patients with chronic lymphocytic leukemia.

Myeloma Expert Previews 2018 ASH Abstracts

November 28th 2018

Ahead of the 2018 ASH Annual Meeting, multiple myeloma experts Sundar Jagannath, MBBS, selected the most pivotal abstracts in their field.

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

January 27th 2018

Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses next steps with the CAR T-cell therapy bb2121 in multiple myeloma.

Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL

January 26th 2018

Frederick Locke, MD, Moffitt Cancer Center, discusses the results of the ZUMA-6 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) in combination with atezolizumab (Tecentriq) for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

Interferon Continues to Show Promise as Myelofibrosis Option

January 4th 2018

Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.

High Response Rate in Histiocytic Disease With MEK Inhibition

January 4th 2018

The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with BRAF-mutated and wild-type histiocytic disorders.

Ropeginterferon Alfa-2b Demonstrates Durable Activity in Polycythemia Vera

December 21st 2017

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.

Pegylated Interferon Alfa-2a Shows Promise in MPNs

December 20th 2017

About two-thirds of patients with hydroxyurea-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia had objective responses to pegylated interferon alfa-2a.

Venetoclax Combo Reaches High CR Rate in Older AML Patients

December 20th 2017

Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.

Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up

December 20th 2017

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.

Selinexor Highly Active in Relapsed/Refractory AML

December 19th 2017

Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.

Selinexor Combo Highly Active in Relapsed/Refractory Myeloma

December 15th 2017

Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.

Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy

December 14th 2017

Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.

New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma

December 14th 2017

The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.

Goy Reflects on MCL Data Presented at ASH 2017

December 13th 2017

Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).

BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma

December 13th 2017

The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.

Elotuzumab/Lenalidomide Maintenance Deepens Responses After Transplant in Myeloma

December 13th 2017

Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.

Ivosidenib Shows High Single-Agent Activity for IDH1-mutant AML

December 13th 2017

The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Oral Anticoagulant Equivalent to Injectable for Cancer VTE

December 13th 2017

Patients with cancer who have venous thromboembolism had similar rates of recurrent VTE or bleeding with the oral factor Xa inhibitor edoxaban (Savaysa) or the low-molecular weight heparin dalteparin (Fragmin).